GleamWall
中文EN

ALGS Aligos Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1799448 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY122.2%
TTM net income YoY23.3%
TTM EPS YoY52.3%
Revenue 3-yr CAGR1.8%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,244.2%
Net margin-1,137.2%
FCF margin—
EBITDA margin-1,223.5%

Returns

ROE-159.5%
ROA-84.5%
ROIC (approx.)-1,147.1%
Asset turnover0.07x

Leverage & solvency

Liabilities / assets76.0%
Debt / equity0.00x
Current ratio1.77x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.03x
Accruals ratio2.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$2.19M$3.61M
R&D expense$69.45M$70.27M
SG&A expense$20.72M$22.83M
Operating income-$87.98M-$89.15M
Pretax income-$23.88M-$130.88M
Income tax$314,000$331,000
Net income-$24.19M-$131.21M
EBITDA-$87.06M-$88.13M
EPS (basic)-2.45-20.94
EPS (diluted)-2.45-20.94
Weighted avg. shares (diluted)9.88M6.26M
Banking
Net interest income$2.20M$1.70M
Balance sheet
Cash & equivalents$18.30M$37.11M
Short-term investments$59.54M$19.94M
Current assets$82.86M$62.14M
PP&E, net$1.87M$2.36M
Total assets$88.53M$70.09M
Current liabilities$21.23M$21.74M
Total liabilities$34.99M$99.07M
Shareholders' equity$53.55M-$28.97M
Shares outstanding6.18M3.86M
Cash flow statement
Operating cash flow-$82.50M-$80.74M
Capital expenditure—$130,000
Free cash flow—-$80.87M
Investing cash flow-$37.83M-$18.28M
Financing cash flow$101.64M$355,000
Depreciation & amortization$930,000$1.03M
Stock-based compensation$5.04M$8.45M

Free plan shows the latest 2 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.